AstraZeneca launches $790M in Euro bonds

AstraZeneca is issuing more bonds to pay off its MedImmune debts. This time, it's an 18-month European issue to the tune of about $790 million; the bonds will be sold to institutions outside the U.S. and trade on the London exchange. The proceeds will cancel U.S. commercial paper the drugmaker took on to finance its buyout of the big biotech firm.

You'll recall that last fall AstraZeneca loosed a whopping $6.9 billion in bonds on the market, also to be used to pay off the MedImmune deal. The bond issue was a big success for the drugmaker, oversubscribed in all tranches.

- see the story at iStock Analyst

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.